Ignite Creation Date:
2024-05-06 @ 12:03 AM
Last Modification Date:
2024-10-26 @ 10:43 AM
Study NCT ID:
NCT01472783
Status:
COMPLETED
Last Update Posted:
2016-11-16
First Post:
2011-11-02
Brief Title:
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation
Sponsor:
Vejle Hospital
Organization:
Vejle Hospital
Study Overview
Official Title:
Veliparib ABT888 Monotherapy for Patients With BRCA Germline Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Veli-BRCA
Brief Summary:
The main purpose of this study is to investigate the effect of veliparib in ovarian cancer patients with known BRCA 12 mutations who do no longer respond to conventional chemotherapy
Detailed Description:
The side effects are modest since PARP inhibitors affect cancer cells to a much larger extent than normal cells The effect of this PARP-inhibiting treatment is evident although the greatest effect is seen in patients with mutations in BRCA genes The reason for this is that BRCA deficient cancer cells are unable to repair both DNA double strand and single strand breaks and undergo apoptosis to a large extent
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None